Molecular Mechanisms of Migraine: Nitric Oxide Synthase and Neuropeptides
Open Access
- 26 July 2023
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (15) , 11993
Abstract
Migraine is a common condition with disabling attacks that burdens people in the prime of their working lives. Despite years of research into migraine pathophysiology and therapeutics, much remains to be learned about the mechanisms at play in this complex neurovascular condition. Additionally, there remains a relative paucity of specific and targeted therapies available. Many sufferers remain underserved by currently available broad action preventive strategies, which are also complicated by poor tolerance and adverse effects. The development of preclinical migraine models in the laboratory, and the advances in human experimental migraine provocation, have led to the identification of key molecules likely involved in the molecular circuity of migraine, and have provided novel therapeutic targets. Importantly, the identification that vasoconstriction is neither necessary nor required for headache abortion has changed the landscape of migraine treatment and has broadened the therapy targets for patients with vascular risk factors or vascular disease. These targets include nitric oxide synthase (NOS) and several neuropeptides that are involved in migraine. The ability of NO donors and infusion of some of these peptides into humans to trigger typical migraine-like attacks has supported the development of targeted therapies against these molecules. Some of these, such as those targeting calcitonin gene-related peptide (CGRP), have already reached clinical practice and are displaying a positive outcome in migraineurs for the better by offering targeted efficacy without significant adverse effects. Others, such as those targeting pituitary adenylate cyclase activating polypeptide (PACAP), are showing promise and are likely to enter phase 3 clinical trials in the near future. Understanding these nitrergic and peptidergic mechanisms in migraine and their interactions is likely to lead to further therapeutic strategies for migraine in the future.Keywords
Funding Information
- Japanese Headache Society
This publication has 263 references indexed in Scilit:
- Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulationExpert Reviews in Molecular Medicine, 2011
- Genome-wide association study reveals three susceptibility loci for common migraine in the general populationNature Genetics, 2011
- Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1Nature Genetics, 2010
- A neural mechanism for exacerbation of headache by lightNature Neuroscience, 2010
- Induction of multiple photophobic behaviors in a transgenic mouse sensitized to CGRPNeuropharmacology, 2010
- Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? A reviewThe Journal of Headache and Pain, 2009
- Body Mass Index, Migraine, Migraine Frequency and Migraine Features in WomenCephalalgia, 2009
- CGRP blockers in migraine therapy: where do they act?British Journal of Pharmacology, 2008
- Y1 receptor knockout increases nociception and prevents the anti-allodynic actions of NPYNutrition, 2008
- Neuron–Glia Signaling in Trigeminal Ganglion: Implications for Migraine PathologyHeadache: The Journal of Head and Face Pain, 2007